ArticleEnvironmental toxicology2025
Dendranthema oreastrum (Hance) Y.Ling Attenuates Oxidative Stress and Airway Inflammation in a Murine Model of Lipopolysaccharide-Induced Acute Lung Injury.
Article in Environmental toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- S100A9 deletion ameliorates acute lung injury by attenuating excessive neutrophil activation via activating the NRF2/HO-1 signaling axis.Respiratory research · 2026Article
- Dendranthema oreastrum (Hance) Y.Ling Attenuates Oxidative Stress and Airway Inflammation in a Murine Model of Lipopolysaccharide-Induced Acute Lung Injury.Environmental toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
We examined the antioxidant and anti-inflammatory effects of the methanolic extract of Dendranthema oreastrum (Hance) Y.Ling, commonly known as "Gu-Jeol-Cho" in Korea and widely found across East Asia, using an LPS-induced acute lung injury (ALI) mouse model and TNF-α-stimulated NCI-H292 cells. LPS was intratracheally administered at 20 μg/50 μL/mouse for 3 days. From test day 1 to 5, experimental mice were administered DO (100 and 200 mg/kg/day) or dexamethasone (3 mg/kg/day). DO treatment decreased pro-inflammatory cytokines in bronchoalveolar lavage fluid and TNF-α-stimulated NCI-H292 cells. Additionally, DO treatment decreased alveolar wall thickening and inflammatory cell infiltration in lung tissues. DO down-regulated TXNIP expression, inhibiting NF-κB activation. Furthermore, DO administration reduced NLRP3 inflammasome activity by preventing the activation of caspase-1 and IL-1β. Additionally, DO promoted the nuclear translocation of Nrf2-related factors, leading to an upregulation of antioxidant enzymes. The study demonstrated that DO administration markedly decreased reactive oxygen species and lipid peroxidation. These observations indicate that DO is a therapeutic agent for ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.